Xenoantigens and xenoantibodies
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Major efforts are being directed towards determining and modifying the glycosylated epitopes on pig vascular endothelial cells, against which human natural antibodies are directed. Genetic engineering techniques are being used in an effort to knock out or replace the major agalactosyl (αGal) epitopes in mice, but to‐date these have been only modestly successful in prolonging functional survival of such modified organs. Competitive glycosylation involving insertion of the gene for α 1,2 fucosyltransferase results in reduction of αGal expression but also of presentation of hitherto cryptic antigens against which natural human antibodies are directed or could develop. The introduction of the gene for N‐acetylglucosaminyltransferase III has been demonstrated to significantly reduce αGal expression, and the intracellular expression of single chain Fv antibodies against α 1,3 galactosyltransferase also represses this enzyme activity. Several other carbohydrate antigens have been identified that could act as targets for human natural antibodies, and these include Galα1–3Le x, Hanganutziu‐Deicher, Tn, and Forssman antigens. The alternative approach, namely, the depletion of the recipient's natural antibodies, is proving difficult, but techniques for inducing B cell tolerance are being explored. The induction of a state of mixed hematopoietic chimerism in αGal knockout mice has resulted in tolerance to the αGal antigen. Tolerance to the SLA antigens of miniature swine is also being attempted in baboons by the transfer of SLA Class II genes into baboon bone marrow cells. It is hoped that one or a combination of these approaches may overcome the problem created by the presence of pig antigens against which humans have xenoreactive antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thall, A. D., Malý, P., & Lowe, J. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21437 · Cited by 401
Cited by
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Glycosylation of Recombinant Antibody Therapeutics
Jefferis, R. (2008) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526
Kannan, R. Y., Salacinski, H. J., Sales, K., Butler, P., & Seifalian, A. M. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.006 · Cited by 373
Anti‐N‐glycolylneuraminic acid antibodies identified in healthy human serum
Zhu, A., & Hurst, R. (2002) · Xenotransplantation · doi:10.1034/j.1399-3089.2002.02138.x · Cited by 273
Tissue Engineering of Small Diameter Vascular Grafts
Teebken, O. E., & Haverich, A. (2002) · European Journal of Vascular and Endovascular Surgery · doi:10.1053/ejvs.2002.1654 · Cited by 268
Metadata
- Authors
- Cooper, D. K. C.
- Venue
- Xenotransplantation
- Publisher
- Wiley
- Published
- 1998-02
- Volume
- 5
- Issue
- 1
- Pages
- 6-17
- ISSN
- 0908-665X (ISSN-L)
- 1399-3089
- OpenAlex
- W2126605149
- Cited by
- 139
- References
- 1
- FWCI
- 14.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Xenoantigens and xenoantibodies. https://app.cochat.ai/papers/10.1111/j.1399-3089.1998.tb00003.x
- The paper
- Cooper, D. K. C. (1998). Xenoantigens and xenoantibodies. Xenotransplantation. https://doi.org/10.1111/j.1399-3089.1998.tb00003.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.